BioXcel Therapeutics, Inc.
BTAI
$1.17
-$0.02-1.68%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 642.00K | 752.00K | 868.00K | 1.85M | 2.27M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 642.00K | 752.00K | 868.00K | 1.85M | 2.27M |
| Cost of Revenue | 164.00K | 964.00K | 2.12M | 2.08M | 2.14M |
| Gross Profit | 478.00K | -212.00K | -1.26M | -226.00K | 122.00K |
| SG&A Expenses | 20.49M | 20.78M | 23.09M | 26.93M | 34.49M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 50.91M | 51.20M | 51.02M | 52.59M | 67.07M |
| Operating Income | -50.27M | -50.45M | -50.15M | -50.74M | -64.80M |
| Income Before Tax | -69.90M | -68.21M | -50.95M | -40.06M | -59.60M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -69.90 | -68.21 | -50.95 | -40.06 | -59.60 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -69.90M | -68.21M | -50.95M | -40.06M | -59.60M |
| EBIT | -50.27M | -50.45M | -50.15M | -50.74M | -64.80M |
| EBITDA | -49.97M | -50.14M | -49.85M | -50.43M | -64.50M |
| EPS Basic | -6.70 | -9.70 | -12.67 | -13.53 | -25.91 |
| Normalized Basic EPS | -4.18 | -6.05 | -7.55 | -7.87 | -15.61 |
| EPS Diluted | -6.70 | -9.70 | -12.67 | -13.53 | -25.91 |
| Normalized Diluted EPS | -4.18 | -6.05 | -7.55 | -7.87 | -15.61 |
| Average Basic Shares Outstanding | 48.73M | 29.91M | 18.37M | 13.04M | 10.13M |
| Average Diluted Shares Outstanding | 48.73M | 29.91M | 18.37M | 13.04M | 10.13M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |